Bristol-Myers Squibb and Karo Bio prolong collaboration
BRISTOL-MYERS SQUIBB AND KARO BIO PROLONG COLLABORATION Bristol-Myers Squibb and Karo Bio announce a prolongation of their collaboration for novel treatments of metabolic diseases. The collaboration started in October 1997 and targeted the development of novel therapies for treatment of obesity, hypercholesterolemia and insulin resistance. The joint research program has been focused on development of substances acting selectively on the thyroid hormone receptor as a way to regulate dysmetabolic syndromes while sparing cardiovascular side effects. "We are very enthusiastic about continuing